Medpace Holdings (MEDP) revenue

Revenue · fiscal 2025
$2.53B

Medpace Holdings (MEDP) reported revenue of $2.53B in fiscal 2025 (the year ended December 31, 2025). That is 20.0% higher than the $2.11B of fiscal 2024. Figures as of 18 Nov 2026, 10:45 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$2.53B
Change on fiscal 2024
+20.0%
Growth, 5 years
+22.3% a year
Growth, 10 years
+21.6% a year
Highest on record
$2.53Bfiscal 2025
Lowest on record
$359.06Mfiscal 2015
Fiscal years on record
112015–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Medpace Holdings revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 22.3% a year; over ten years the rate was 21.6% a year. Across the 11 fiscal years on record (2015–2025), the highest was $2.53B in fiscal 2025 and the lowest $359.06M in fiscal 2015.

History · 11 fiscal years

Revenue by fiscal year

Medpace Holdings revenue, year by year

Medpace Holdings (MEDP) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$2.53B 20.0% up
2024$2.11B 11.8% up
2023$1.89B 29.2% up
2022$1.46B 27.8% up
2021$1.14B 23.4% up
2020$925.93M 7.5% up
2019$860.97M 22.2% up
2018$704.59M 61.5% up
2017$436.15M 3.5% up
2016$421.58M 17.4% up
2015$359.06M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Medpace Holdings and comparable companies
CompanyRevenueFiscal year
Alnylam Pharmaceuticals ALNY$3.71B2025
Zimmer Biomet Holdings ZBH$8.23B2025
Medpace Holdings MEDP$2.53B2025
Revvity RVTY$2.86B2025
Exelixis EXEL$2.32B2025
Charles River Laboratories International CRL$4.02B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on MEDP

Medpace Holdings, figure by figure

Medpace Holdings (MEDP) overview: price, valuation and scorecardAll health care companies by market value

Medpace Holdings revenue: questions and answers

What is Medpace Holdings's revenue?

Medpace Holdings (MEDP) reported revenue of $2.53B in fiscal 2025 (the year ended December 31, 2025). That is 20.0% higher than the $2.11B of fiscal 2024.

What is the growth rate of Medpace Holdings's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 22.3% a year; over ten years the rate was 21.6% a year.

What are the highest and lowest revenue figures on record for Medpace Holdings?

Across the 11 fiscal years on record (2015–2025), the highest was $2.53B in fiscal 2025 and the lowest $359.06M in fiscal 2015.

How is Medpace Holdings's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Medpace Holdings it is on record here for 11 fiscal years, 2015 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Medpace Holdings (MEDP) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/MEDP/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.